Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Multiple sclerosis (MS) is considered to be an autoimmune, inflammatory disease of the
CNS. In most patients, the disease follows a relapsing–remitting course and is characterized …

Some recent studies suggest that in progressive multiple sclerosis, neurodegeneration may
occur independently from inflammation. The aim of our study was to analyse the …

Each year about 650,000 Europeans die from stroke and a similar number lives with the
sequelae of multiple sclerosis (MS). Stroke and MS differ in their etiology. Although cause …

Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative
pathology. Axonal loss and neurodegeneration occurs early in the disease course and may …

The use of magnetic resonance imaging as a surrogate outcome measure in clinical trials, or
even as a prognosticator in the assessment of the natural evolution, assumes a close …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system
characterized by focal or diffuse inflammation, demyelination, axonal loss and …

Objective To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at
all stages of disease, and to identify predictors and clinical correlates of GM atrophy …

MRI methods are widely used to follow the pathological evolution of multiple sclerosis in life
and its modification by treatment. To date, measures of the number and volume of …

Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …